Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HS-10375 in advanced non-small cell lung cancer
CTR20220045Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hs-10375 in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Mar 2022; status: active.
02
Drugs
hs-10375
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220045.